Search
Coherus BioSciences Inc
CHRSAdd to Watchlist
1.430USD
+0.100+7.52%
Close 09-14 16:00（ET）
220.12MMarket Cap
0.87P/E TTM
Coherus BioSciences Inc (CHRS) Revenue Performance
Updated: Jun 30, 2026Last year, Coherus BioSciences Inc generated 76.03M USD for its biggest-performing segment, UDENYCA. The United States made the largest contribution, accounting for 42.17M USD last year. For the latest quarter, Coherus BioSciences Inc reported the revenue of 13.61M USD for the period ending 2026-06-30, which came from the top-performing segment, LOQTORZI. United States contributed the highest revenue, at 14.31M USD.
By Business
Revenue
Proportion
Annual
Annual
Quarterly
UDENYCA
CIMERLI
YUSIMRY
LOQTORZI
Other
FY2025
FY2024
FY2023
UDENYCA
76.03M(99.24%)
205.95M(77.15%)
127.06M(49.39%)
CIMERLI
515.00K(0.67%)
27.08M(10.14%)
125.39M(48.74%)
YUSIMRY
67.00K(0.09%)
7.54M(2.82%)
3.57M(1.39%)
LOQTORZI
--(--)
19.13M(7.17%)
554.00K(0.22%)
Other
--(--)
7.26M(2.72%)
664.00K(0.26%)
By Region
Revenue
Proportion
Annual
Annual
Quarterly
United States
United states
Rest of the world
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
United States
42.17M(100.00%)
266.96M(100.00%)
257.24M(100.00%)
211.04M(100.00%)
--(--)
--(--)
--(--)
--(--)
United states
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
356.07M(100.00%)
--(--)
Rest of the world
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)